Physician profile
Tanner Rawlings
NPI 1558897579
$6,362.76
in general payments reported to CMS, 2019-2025
35 companies · $1,321 in 2025
The $1,321 reported for 2025 was more than what a typical Urology provider received nationally (typical 2025 total: $631).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $543 · 2023: $2,758 · 2024: $1,740 · 2025: $1,321.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,012 · Travel and Lodging: $1,808.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,011.63 |
| Travel and Lodging | $1,808.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boston Scientific Corporation | $2,026.61 | 2022-2025 | Lithovue, Lumenis Pulse 120h, Moses 550 D\F\L |
| Procept Biorobotics Corporation | $780.88 | 2023-2024 | Aquabeam System, Aquabeam Robotic System |
| Coloplast Corp | $499.95 | 2023 | Titan |
| Janssen Biotech, INC. | $425.60 | 2022-2025 | Erleada, Carvykti, Rybrevant |
| Sumitomo Pharma America, INC. | $306.95 | 2023-2025 | Orgovyx, Gemtesa |
| Astellas Pharma US INC | $296.00 | 2022-2025 | Myrbetriq, Xtandi |
| Ferring Pharmaceuticals INC. | $255.82 | 2024-2025 | Adstiladrin |
| Dendreon Pharmaceuticals LLC | $173.52 | 2023-2025 | Provenge |
| Ambu INC. | $139.69 | 2024-2025 | |
| Merck Sharp & Dohme LLC | $127.43 | 2023-2025 | Lynparza, Keytruda, Welireg |
| Innovation Technologies INC | $117.39 | 2022-2025 | Irrisept |
| Cook Medical LLC | $117.24 | 2022 | |
| Pfizer INC. | $116.92 | 2024-2025 | |
| Blue Earth Diagnostics | $107.38 | 2023-2024 | |
| Valencia Technologies Corporation | $92.74 | 2025 | Ecoin Device Kit |
Show all 35 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Accord Healthcare, INC. | $91.11 | 2024-2025 | |
| Axonics, INC. | $55.11 | 2022-2024 | Axonics |
| Immunitybio, INC. | $54.22 | 2025 | |
| Abbvie INC. | $53.09 | 2023-2024 | |
| Antares Pharma, INC. | $52.26 | 2022-2025 | Xyosted |
| Tempus Ai, INC | $49.18 | 2024-2025 | Xt Cdx |
| Urogen Pharma, INC. | $44.62 | 2023-2024 | Jelmyto |
| Endo USA, INC. | $41.72 | 2024-2025 | Xiaflex, Aveed |
| Urovant Sciences INC | $40.98 | 2022 | |
| Novartis Pharmaceuticals Corporation | $40.77 | 2023-2024 | |
| Olympus America INC. | $38.73 | 2023-2024 | Itind System |
| Progenics Pharmaceuticals, INC. | $36.38 | 2022-2024 | |
| Myriad Genetic Laboratories, INC. | $33.41 | 2023-2024 | Prolaris |
| Baxter Healthcare | $24.98 | 2024 | Floseal |
| Bayer Healthcare Pharmaceuticals INC. | $24.81 | 2023 | |
| Tolmar, INC. | $24.72 | 2023 | |
| Medtronic, INC. | $22.43 | 2025 | Interstim |
| Calyxo, INC. | $22.01 | 2025 | Cvac Aspiration System |
| Telix Pharmaceuticals | $20.78 | 2024 | Illuccix |
| Mission Pharmacal Company | $7.33 | 2024 | Uribel Tabs |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Tanner Rawlings listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.